open access

Vol 52, No 4 (2021)
Review article
Published online: 2021-08-31
Submitted: 2021-07-14
Accepted: 2021-07-14
Get Citation

Treatment of Hodgkin lymphoma relapse after autologous hematopoietic cell transplantation

Justyna Rybka1, Tomasz Wróbel1
DOI: 10.5603/AHP.2021.0059
·
Acta Haematol Pol 2021;52(4):309-313.
Affiliations
  1. Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland

open access

Vol 52, No 4 (2021)
REVIEW ARTICLE
Published online: 2021-08-31
Submitted: 2021-07-14
Accepted: 2021-07-14

Abstract

Despite the high response rate to first-line treatment, approximately 10% of patients with Hodgkin lymphoma (HL) develop primary resistance to chemotherapy, and 10–30% of patients experience relapse. Today, salvage chemotherapy with subsequent autologous stem cell transplantation (ASCT) remains the standard of care for those patients with relapsed/refractory HL (RRHL). Treating patients with HL who relapse following ASCT continues to be a difficult clinical challenge. For many years, allogeneic hematopoietic stem cell transplantation was the only therapeutic option in this patient population. The last decade has brought new treatment options for RRHL patients with immunotherapy, including: brentuximab vedotin anti-CD30 monoclonal antibody, or the checkpoint inhibitors nivolumab and pembrolizumab, or advanced immune therapies such as bispecific antibodies, or chimeric antigen receptor T-cell therapy.

Abstract

Despite the high response rate to first-line treatment, approximately 10% of patients with Hodgkin lymphoma (HL) develop primary resistance to chemotherapy, and 10–30% of patients experience relapse. Today, salvage chemotherapy with subsequent autologous stem cell transplantation (ASCT) remains the standard of care for those patients with relapsed/refractory HL (RRHL). Treating patients with HL who relapse following ASCT continues to be a difficult clinical challenge. For many years, allogeneic hematopoietic stem cell transplantation was the only therapeutic option in this patient population. The last decade has brought new treatment options for RRHL patients with immunotherapy, including: brentuximab vedotin anti-CD30 monoclonal antibody, or the checkpoint inhibitors nivolumab and pembrolizumab, or advanced immune therapies such as bispecific antibodies, or chimeric antigen receptor T-cell therapy.

Get Citation

Keywords

Hodgkin lymphoma, brentuximab vedotin, nivolumab, autologous stem cell transplantation, allogeneic stem cell transplantation

About this article
Title

Treatment of Hodgkin lymphoma relapse after autologous hematopoietic cell transplantation

Journal

Acta Haematologica Polonica

Issue

Vol 52, No 4 (2021)

Article type

Review article

Pages

309-313

Published online

2021-08-31

DOI

10.5603/AHP.2021.0059

Bibliographic record

Acta Haematol Pol 2021;52(4):309-313.

Keywords

Hodgkin lymphoma
brentuximab vedotin
nivolumab
autologous stem cell transplantation
allogeneic stem cell transplantation

Authors

Justyna Rybka
Tomasz Wróbel

References (42)
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7–30.
  2. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018; 93(5): 704–715.
  3. Mehta-Shah N, Bartlett NL. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. Blood. 2018; 131(15): 1698–1703.
  4. Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J Hematol. 2017; 92(9): 879–884.
  5. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant. 1997; 20(1): 21–26.
  6. Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010; 148(6): 890–897.
  7. Sureda A, Constans M, Iriondo A, et al. Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005; 16(4): 625–633.
  8. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol. 2004; 124(5): 645–652.
  9. Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2008; 19(7): 1312–1319.
  10. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study — a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the lymphoma working party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012; 97(2): 310–317.
  11. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30(18): 2183–2189.
  12. Chen R, Gopal A, Smith S, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016; 128(12): 1562–1566.
  13. Connors M, Jurczak W, Straus D, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018; 378(4): 331–344.
  14. Moskowitz A, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015; 16(3): 284–292.
  15. Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019; 30(4): 612–620.
  16. Moskowitz CH, Nademanee A, Masszi T, et al. AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385(9980): 1853–1862.
  17. Moskowitz C, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018; 132(25): 2639–2642.
  18. Eichenauer DA, Aleman BMP, André M, et al. ESMO Guidelines Committee. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv19–iv29.
  19. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014; 7: 24.
  20. Roemer MGM, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016; 34(23): 2690–2697.
  21. Riella LV, Paterson AM, Sharpe AH, et al. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012; 12(10): 2575–2587.
  22. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study. Lancet Oncol. 2016; 17(9): 1283–1294.
  23. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/ refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cel transplantation. Extended follow-up of the multicohort single-arm phase CheckMate 205 trial. J Clin Oncol. 2017; 35: 2125–2132.
  24. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol. 2018; 36(14): 1428–1439.
  25. Kuruvilla J, Ramchandren R, Santoro A, et al. KEYNOTE-204 investigators. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021; 22(4): 512–524.
  26. Diefenbach C, Hong F, David K, et al. Title: a phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412 arms d and E). Blood. 2016; 128(22): 1106.
  27. Diefenbach C, Hong F, Ambinder R, et al. A phase i study with an expansion cohort of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412: arms G-I). Blood. 2018; 132(Suppl 1): 679.
  28. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol. 1993; 11(12): 2342–2350.
  29. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008; 26(3): 455–462.
  30. Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017; 129(18): 2471–2478.
  31. Merryman R, Kim H, Zinzani P, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017; 129(10): 1380–1388.
  32. De Philippis C, Legrand-Izadifar F, Bramanti S, et al. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv. 2020; 4(7): 1242–1249.
  33. Herbaux C, Merryman R, Devine S, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018; 132(1): 9–16.
  34. Grover N, Park S, Ivanova A, et al. A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+ Lymphomas. Biol Blood Marrow Transplant. 2019; 25: S66.
  35. Ramos C, Grover N, Beaven A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020; 38(32): 3794–3804.
  36. Voorhees T, Grover N, Beaven A, et al. Retrospective cohort study analyzing the safety and efficacy of anti-PD-1 therapy following CD30 CAR-T cell therapy in relapsed/refractory Hodgkin lymphoma. Blood. 2019; 134(Suppl 1): 3233.
  37. Berg Av, Visser L, Poppema S. High Expression of the CC Chemokine TARC in Reed–Sternberg Cells. Am J Pathol. 1999; 154(6): 1685–1691.
  38. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. J Clin Oncol. 2014; 32(8): 798–808.
  39. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116(17): 3268–3277.
  40. Van Den Neste E, André M, Gastinne T, et al. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica. 2018; 103(5): 840–848.
  41. Bartlett N, Chen R, Domingo-Domenech E, et al. A phase 1b study investigating the combination of the tetravalent bispecific NK cell engager AFM13 and pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure: updated safety and efficacy data. Blood. 2018; 132(Suppl 1): 1620.
  42. Hamadani M, Balasubramanian S, Hari PN. Ibrutinib in refractory classic Hodgkin's lymphoma. N Engl J Med. 2015; 373(14): 1381–1382.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl